Enhancement updates provide short alerts to new, fixed or improved Connect Care functions...
- Conditional After Visit Summary for Aprepitant and Sugammadex
As of September 11, 2026, if a patient was administered Aprepitant (Emend) or Sugammadex (Bridion) while undergoing anesthesia and they meet the below criteria, an advisory warning will appear in their After Visit Summary (AVS) to advise that hormonal birth control effectiveness will be temporarily decreased due to potential drug interactions, and that additional/alternative contraception is recommended. Previously, Our Practice Advisories (OPAs) were only triggered for clinicians if the legal sex in their patient record was set to "Female", and patient education may have been missed particularly as contraceptive use is not always disclosed/documented.
This advisory will appear in a patient's AVS if the patient:
- Is between 9 and 55 years old
- Is documented as "Female" or "Female sex at birth"
- Is not currently pregnant
- Has no documented history of hysterectomy AND
- Sugammadex has been administered in the past 7 days OR
- Aprepitant has been administered in the past 30 days
Click the below camera icon to see screenshots of how the advisories will appear in the AVS.